Company / PP&E (Net)
4D Molecular Therapeutics, Inc. PP&E (Net) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$14.9M
FY2025
5-year range
$14.4M / $22.3M
FY2021-FY2025
Trend
-23.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $22M in FY2022 to $15M in FY2025.
Based on SEC 10-K filings.
$15M in FY2025 with a 5-year CAGR of +24.0%.
Declined from $20M to $15M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -12.6%
- 5-Year CAGR
- +24.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 4D Molecular Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of +24.0%, indicating consistent growth.
- In FY2025, pp&e (net) decreased 23.9% year-over-year.
- Peak pp&e (net) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.9M | -23.9% |
| FY2024 | $19.5M | -2.9% |
| FY2023 | $20.1M | -9.6% |
| FY2022 | $22.3M | +54.7% |
| FY2021 | $14.4M | +183.7% |
| FY2020 | $5.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026